がん診断の世界市場：2025年～2033年

世界のがん診断の市場規模は、2024年に217億1,000万米ドルに達し、2033年には426億4,000万米ドルに達すると予測され、2025年から2033年の予測期間中のCAGRは8.7％と見込まれています。

世界のがん診断市場は、さまざまな種類のがん、特に早期がんの検出と診断に使用される医療機器、ツール、技術、サービスに焦点を当てた産業を包括しています。この市場には、画像診断法（MRI、CTスキャン、PETスキャンなど）、分子・遺伝子検査（次世代シーケンシング、リキッドバイオプシーなど）、病理検査、がん関連バイオマーカーの同定に役立つスクリーニング技術など、幅広い診断ソリューションが含まれます。

これらの診断ツールの主な目的は、正確でタイムリーながん発見を提供し、より効果的で個別化された治療選択肢を可能にし、最終的に患者の転帰と生存率を改善することです。同市場は、がん罹患率の増加、診断技術の継続的な進歩、早期発見と個別化されたがん治療に対する需要の増加によって支えられています。

がんの罹患率と有病率の上昇は、がん診断市場の成長を大きく後押ししており、予測期間中も市場を牽引するとみられます。例えば、2022年のGloboconのデータによると、男性のがん罹患率は1,030万人、女性は970万人でした。2025年には、がん罹患率は男性で1,250万人、女性で1,160万人に達すると予測されています。このような罹患率の増加は、アクセスしやすく費用対効果の高いがん診断ソリューションの緊急ニーズを浮き彫りにしています。

高齢者はがんを開発しやすいため、世界人口の高齢化はがんリスクの上昇に寄与しています。このような人口動態の変化により、がん患者数が増加しており、がんを早期に発見し、最終的に治療成績を向上させる診断検査に対する需要が高まっていることを示しています。

その結果、がん罹患者数の増加は、がん診断の需要を直接的に押し上げ、関連製品・サービスの市場拡大につながります。これには、さまざまな種類のがんを特定しモニタリングするために不可欠な診断検査、画像診断システム、検査室サービスが含まれます。このような世界の動向は、先進的な診断技術に対する差し迫ったニーズを生み出し、市場の成長を促すとともに、世界のがん医療の格差に対処することの重要性を強調しています。

診断手技や機器のコストが高いことは、がん診断市場の成長にとって大きな障壁となっています。がんの早期かつ正確な発見にはいくつかの先進的な診断ツールが不可欠であるが、その導入に伴う高額な費用が大きな課題となる可能性があります。次世代シーケンシング（NGS）、リキッドバイオプシー、高解像度画像診断システムなど、これらのツールには直接的・間接的なコストが伴うため、その利用しやすさや普及には限界があります。

研究者らによると、2021年の初回がん検診の年間推定費用430億米ドルは、米国で報告されている診断後12ヵ月のがん治療の年間費用よりも低いです。研究者らは、がん検診費用とその根底にある要因を理解することは、政策決定に情報を提供し、推奨されるがん検診サービスへのアクセスを改善することを目的としたプログラムの開発を導くために極めて重要であると強調しています。

高度な診断技術には多額の先行投資が必要です。例えば、NGSシステムは数10万米ドルもし、PET/CTスキャナーやMRIのような高解像度画像診断装置は数100万米ドルもします。特に中低所得国の小規模な病院、クリニック、ヘルスケア施設にとっては、これらの機器の購入価格が大きな障壁となります。

当レポートでは、世界のがん診断市場について調査し、市場の概要とともに、製品別、適応症別、地域別動向、競合情勢、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 市場のイントロダクションと範囲

第2章 経営者の洞察と重要なポイント

第3章 市場力学

• 影響要因
  • 促進要因
  • 抑制要因
  • 機会
  • 影響分析

第4章 戦略的洞察と業界見通し

• 市場のリーダーとパイオニア
• CXOの視点
• 最新の開発とブレークスルー
• ケーススタディ/進行中の調査
• 規制と償還の情勢
• ポーターのファイブフォース分析
• サプライチェーン分析
• 特許分析
• SWOT分析
• アンメットニーズとギャップ
• 市場参入と拡大のための推奨戦略
• シナリオ分析ベストケース、ベースケース、ワーストケースの予測
• 価格分析と価格動向
• キーオピニオンリーダー

第5章 がん診断市場（製品別）

• 消耗品
• 機器
• 画像機器
• バイオマーカーベース
• 生検器具

第6章 がん診断市場（適応症別）

• 乳がん
• 大腸がん
• 子宮頸がん
• 肺がん
• 前立腺がん
• 皮膚がん
• 血液がん
• 腎臓がん
• 肝臓がん
• 膵臓がん
• 卵巣がん
• その他

第7章 がん診断市場、地域別市場分析と成長機会

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他
• 南米
  • ブラジル
  • アルゼンチン
  • その他
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他
• 中東・アフリカ

第8章 競合情勢と市場ポジショニング

• 競合状況の概要と主要市場参入企業
• 市場シェア分析とポジショニングマトリックス
• 戦略的パートナーシップ、合併・買収
• 製品ポートフォリオとイノベーションにおける主な発展
• 企業ベンチマーク

第9章 企業プロファイル

• F. Hoffmann-La Roche Ltd
• 会社概要
• 製品ポートフォリオ
• 財務概要
• 主な発展
• SWOT分析
• Abbott.
• Thermo Fisher Scientific Inc.
• Siemens Healthcare Private Limited
• GE HealthCare.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Hologic, Inc.
• Koninklijke Philips NV,
• BD.
• QIAGEN

第10章 前提と調査手法

第11章 付録

The global cancer diagnostics market reached US$ 21.71 billion in 2024 and is expected to reach US$ 42.64 billion by 2033, growing at a CAGR of 8.7% during the forecast period of 2025-2033.

The global cancer diagnostics market encompasses the industry focused on medical devices, tools, technologies, and services used to detect and diagnose various types of cancer, particularly at early stages. This market includes a wide array of diagnostic solutions, such as imaging methods (e.g., MRI, CT scans, PET scans), molecular and genetic tests (e.g., next-generation sequencing, liquid biopsy), pathology tests, and screening techniques that help identify cancer-related biomarkers.

The primary objective of these diagnostic tools is to provide accurate and timely cancer detection, enabling more effective, personalized treatment options and ultimately improving patient outcomes and survival rates. The market is propelled by the growing prevalence of cancer, ongoing advancements in diagnostic technologies, and increasing demand for early detection and personalized cancer care.

Market Dynamics: Drivers & Restraints

Rising Incidence and Prevalence Of Cancer

The rising incidence and prevalence of cancer are significantly driving the growth of the diagnostics for the cancer market and are expected to drive the market over the forecast period. For instance, according to the Globocon data in 2022, the cancer incidence for males was 10.3 million, while for females, it was 9.7 million. By 2025, the cancer incidence is projected to reach 12.5 million for males and 11.6 million for females. This escalating incidence highlights the urgent need for accessible and cost-effective cancer diagnostics solutions.

The aging global population is contributing to a higher risk of cancer, as older individuals are more susceptible to developing the disease. This demographic shift has resulted in a rise in cancer cases, highlighting the increasing demand for diagnostic tests that can detect cancer at earlier stages, ultimately improving treatment outcomes.

As a result, the rising number of cancer cases directly boosts the demand for cancer diagnostics, leading to a growing market for related products and services. This includes diagnostic tests, imaging systems, and laboratory services that are crucial for identifying and monitoring different types of cancer. These trends create a pressing need for advanced diagnostic technologies, fuel market growth, and underscore the importance of addressing disparities in cancer care globally.

High Costs of Diagnostic Procedures and Equipment

High costs of diagnostic procedures and equipment are a significant barrier to the growth of diagnostics for the cancer market. Several advanced diagnostic tools are essential for the early and accurate detection of cancer, but the high expenses associated with their implementation can create significant challenges. These tools, such as next-generation sequencing (NGS), liquid biopsy, and high-resolution imaging systems, come with a combination of direct and indirect costs that limit their accessibility and widespread use.

According to the researchers, the estimated $43 billion annual cost for initial cancer screening in 2021 is lower than the reported annual cost of cancer treatment in the U.S. during the first 12 months following diagnosis. They emphasize that understanding cancer screening costs and their underlying factors is crucial for informing policy decisions and guiding the development of programs aimed at improving access to recommended cancer screening services.

Advanced diagnostic technologies require a substantial upfront investment. For instance, NGS systems can cost hundreds of thousands of dollars, and high-resolution imaging machines like PET/CT scanners or MRI machines can cost millions. The price of purchasing these machines is a major barrier, especially for smaller hospitals, clinics, or healthcare facilities in low- and middle-income countries.

Segment Analysis

The global cancer diagnostics market is segmented based on product, indication, and region.

Product:

The consumables segment in the product is expected to dominate the global cancer diagnostics market with the highest market share

Consumables in cancer diagnostics encompass the single-use or limited-use materials necessary for conducting various diagnostic tests. These items play a critical role in ensuring accurate, reliable, and efficient cancer detection. These items are critical for every step of the diagnostic process, from sample collection and processing to the execution of complex assays.

Consumables are the backbone of the day-to-day operations in cancer diagnostic laboratories. They ensure that every step of the testing process, from sample collection to final analysis, adheres to rigorous quality standards, ultimately improving early detection, treatment planning, and patient outcomes.

Consumables include antibodies, kits & reagents, probes, and other related tools form the foundation of modern cancer diagnostics. They empower clinicians to perform precise, dependable, and increasingly personalized tests, leading to earlier cancer detection and customized treatment strategies for individual patients.

Furthermore, key players in the industry are making innovative launches that would drive this segment's growth in the market. For instance, in August 2024, Oncosure developed and launched a rapid cancer screening test that can detect all types of cancer using just a single blood draw. This indicates that Oncosure has developed and launched an innovative diagnostic tool that rapidly identifies cancer. These factors have solidified the segment's position in the global cancer diagnostics market.

Geographical Analysis

North America is expected to hold a significant position in the global cancer diagnostics market, with the highest market share

North America is expected to hold the largest market share in the global cancer diagnostics market. North America, particularly the United States, has a high cancer prevalence, which fuels the demand for cancer diagnostics solutions.

According to the National Institutes of Health (NIH) data in May 2024, cancer has a significant impact on society both in the United States and globally. Cancer statistics offer insight into the scope of the disease and reflect its burden on society. In 2024, it is estimated that 2,001,140 new cases of cancer will be diagnosed in the United States, and 611,720 people will succumb to the disease. The escalating incidence of cancer underscores the urgent need for cancer diagnostics solutions that are both accessible and cost-effective.

The field of early cancer screening is in dire need of a revolution. Over the next 30 years, more than 40 million Americans are expected to be diagnosed with late-stage cancer, representing 44% of all new cancer diagnoses in the U.S. In this region, a major number of key players are present, including government initiatives, programs, and product approvals that would drive this market growth.

For instance, in February 2024, the National Institutes of Health (NIH) launched the Cancer Screening Research Network (CSRN) to evaluate and advance emerging technologies for cancer screening. This initiative is part of the broader efforts to support the Biden-Harris administration's Cancer Moonshot initiative, which aims to accelerate progress in cancer research and reduce cancer mortality by making significant advances in early detection and treatment.

Also, in August 2024, the Biden-Harris Administration's ARPA-H (Advanced Research Projects Agency for Health) launched a new program aimed at developing an at-home multi-cancer screening test. This initiative is designed to revolutionize the way we detect cancers, especially those that are difficult to diagnose early.

Similarly, in August 2024, Illumina, Inc. announced that the Food and Drug Administration (FDA) had approved its TruSight Oncology (TSO) Comprehensive test as an in vitro diagnostic (IVD) tool, along with its first two companion diagnostic (CDx) indications. This approval marks a significant advancement in cancer diagnostics, providing a valuable tool for both clinicians and patients. Thus, the above factors are consolidating the region's position as a dominant force in the global cancer diagnostics market.

Competitive Landscape

The major global players in the cancer diagnostics market include F. Hoffmann-La Roche Ltd, Abbott, Thermo Fisher Scientific Inc., Siemens Healthcare Private Limited, GE HealthCare, Illumina, Inc., Bio-Rad Laboratories, Inc., Hologic, Inc., Koninklijke Philips N.V., BD, and QIAGEN, among others.

Key Developments

• In January 2025, Roche received FDA approval for a companion diagnostic-a test designed to identify patients who are most likely to benefit from a specific treatment. In this case, the test determines whether patients with HER2-ultralow metastatic breast cancer are eligible for treatment with ENHERTU.
• In September 2024, Roche announced an expansion of its digital pathology platform by integrating over 20 advanced AI algorithms from eight new collaborators. Digital pathology involves scanning traditional glass microscope slides and analyzing them using digital tools, including AI, to improve diagnostic accuracy and efficiency.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials and product pipelines and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzed product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: This covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyze competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global cancer diagnostics market report delivers a detailed analysis with 57 key tables, more than 51 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

• 1.1. Objectives of the Report
• 1.2. Report Coverage & Definitions
• 1.3. Report Scope

2. Executive Insights and Key Takeaways

• 2.1. Market Highlights and Strategic Takeaways
• 2.2. Key Trends and Future Projections
• 2.3. Snippet by Product
• 2.4. Snippet by Indication
• 2.5. Snippet by Region

3. Dynamics

• 3.1. Impacting Factors
  • 3.1.1. Drivers
    • 3.1.1.1. Advancements in Diagnostic Technologies
    • 3.1.1.2. Rising Prevalence of Cancer
  • 3.1.2. Restraints
    • 3.1.2.1. High Costs of Diagnostic Procedures and Equipment
    • 3.1.2.2. Limited Accessibility in Developing Regions
  • 3.1.3. Opportunity
    • 3.1.3.1. Growth in Early Detection and Screening Programs
  • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

• 4.1. Market Leaders and Pioneers
  • 4.1.1. Emerging Pioneers and Prominent Players
  • 4.1.2. Established leaders with the largest-selling Brand
  • 4.1.3. Market leaders with established Product
• 4.2. CXO Perspectives
• 4.3. Latest Developments and Breakthroughs
• 4.4. Case Studies/Ongoing Research
• 4.5. Regulatory and Reimbursement Landscape
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia Pacific
  • 4.5.4. South America
  • 4.5.5. Middle East & Africa
• 4.6. Porter's Five Forces Analysis
• 4.7. Supply Chain Analysis
• 4.8. Patent Analysis
• 4.9. SWOT Analysis
• 4.10. Unmet Needs and Gaps
• 4.11. Recommended Strategies for Market Entry and Expansion
• 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
• 4.13. Pricing Analysis and Price Dynamics
• 4.14. Key Opinion Leaders

5. Cancer Diagnostics Market, By Product

• 5.1. Introduction
  • 5.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
  • 5.1.2. Market Attractiveness Index, By Product
• 5.2. Consumables*
  • 5.2.1. Introduction
  • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.2.3. Antibodies
  • 5.2.4. Kits & Reagents
  • 5.2.5. Probes
  • 5.2.6. Others
• 5.3. Instruments
  • 5.3.1. Pathology-based Instruments
    • 5.3.1.1. Tissue Processing Systems
    • 5.3.1.2. Cell Processors
    • 5.3.1.3. PCR Instruments
    • 5.3.1.4. NGS Instruments
    • 5.3.1.5. Microarrays
    • 5.3.1.6. Others
• 5.4. Imaging Instruments
  • 5.4.1.1. CT Systems
  • 5.4.1.2. Ultrasound Systems
  • 5.4.1.3. MRI Systems
  • 5.4.1.4. Mammography Systems
  • 5.4.1.5. Others
• 5.5. Biomarker-Based
• 5.6. Biopsy Instruments

6. Cancer Diagnostics Market, By Indication

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 6.1.2. Market Attractiveness Index, By Indication
• 6.2. Breast Cancer*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Colorectal Cancer
• 6.4. Cervical Cancer
• 6.5. Lung Cancer
• 6.6. Prostate Cancer
• 6.7. Skin Cancer
• 6.8. Blood Cancer
• 6.9. Kidney Cancer
• 6.10. Liver Cancer
• 6.11. Pancreatic Cancer
• 6.12. Ovarian Cancer
• 6.13. Others

7. Cancer Diagnostics Market, By Regional Market Analysis and Growth Opportunities

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 7.1.2. Market Attractiveness Index, By Region
• 7.2. North America
  • 7.2.1. Introduction
  • 7.2.2. Key Region-Specific Dynamics
  • 7.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.2.5.1. U.S.
    • 7.2.5.2. Canada
    • 7.2.5.3. Mexico
• 7.3. Europe
  • 7.3.1. Introduction
  • 7.3.2. Key Region-Specific Dynamics
  • 7.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.3.5.1. Germany
    • 7.3.5.2. U.K.
    • 7.3.5.3. France
    • 7.3.5.4. Spain
    • 7.3.5.5. Italy
    • 7.3.5.6. Rest of Europe
• 7.4. South America
  • 7.4.1. Introduction
  • 7.4.2. Key Region-Specific Dynamics
  • 7.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.4.5.1. Brazil
    • 7.4.5.2. Argentina
    • 7.4.5.3. Rest of South America
• 7.5. Asia-Pacific
  • 7.5.1. Introduction
  • 7.5.2. Key Region-Specific Dynamics
  • 7.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  • 7.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 7.5.5.1. China
    • 7.5.5.2. India
    • 7.5.5.3. Japan
    • 7.5.5.4. South Korea
    • 7.5.5.5. Rest of Asia-Pacific
• 7.6. Middle East and Africa
  • 7.6.1. Introduction
  • 7.6.2. Key Region-Specific Dynamics
  • 7.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  • 7.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

8. Competitive Landscape and Market Positioning

• 8.1. Competitive Overview and Key Market Players
• 8.2. Market Share Analysis and Positioning Matrix
• 8.3. Strategic Partnerships, Mergers & Acquisitions
• 8.4. Key Developments in Product Portfolios and Innovations
• 8.5. Company Benchmarking

9. Company Profiles

• 9.1. F. Hoffmann-La Roche Ltd*
  • 9.1.1. Company Overview
  • 9.1.2. Product Portfolio
    • 9.1.2.1. Product Description
    • 9.1.2.2. Product Key Performance Indicators (KPIs)
    • 9.1.2.3. Historic and Forecasted Product Sales
    • 9.1.2.4. Product Sales Volume
  • 9.1.3. Financial Overview
    • 9.1.3.1. Company Revenue
    • 9.1.3.2. Geographical Revenue Shares
    • 9.1.3.3. Revenue Forecasts
  • 9.1.4. Key Developments
    • 9.1.4.1. Mergers & Acquisitions
    • 9.1.4.2. Key Product Development Activities
    • 9.1.4.3. Regulatory Approvals, etc.
  • 9.1.5. SWOT Analysis
• 9.2. Abbott.
• 9.3. Thermo Fisher Scientific Inc.
• 9.4. Siemens Healthcare Private Limited
• 9.5. GE HealthCare.
• 9.6. Illumina, Inc.
• 9.7. Bio-Rad Laboratories, Inc.
• 9.8. Hologic, Inc.
• 9.9. Koninklijke Philips N.V.,
• 9.10. BD.
• 9.11. QIAGEN

LIST NOT EXHAUSTIVE

10. Assumptions and Research Methodology

• 10.1. Data Collection Methods
• 10.2. Data Triangulation
• 10.3. Forecasting Techniques
• 10.4. Data Verification and Validation

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us